Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Predictors of the incidence of all-cause mortality and deaths due to diabetes and renal diseases among patients newly prescribed antihypertensive agents: A cohort study

Martin C.S. Wong a, Wilson W.S. Tam a,⁎, Harry H.X. Wang a, Clement S.K. Cheung b, Ellen L.H. Tong b, Antonio C.H. Sek b, N.T. Cheung b, Bryan P.Y. Yan c, C.M. Yu c, Stephen R. Leeder d, Sian M. Griffiths a

a Jockey Club School of Public Health and Primary Care, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong
b Hospital Authority Information Technology Services—Health Informatics Section, Hong Kong
c Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong
d Menzies Centre for Health Policy, University of Sydney, Australia

ARTICLE INFO

Article history:
Received 6 February 2013
Received in revised form 18 July 2013
Accepted 20 July 2013
Available online 26 July 2013

Keywords:
- All-cause mortality
- Diabetes mellitus
- Renal disease
- Antihypertensive drug class

ABSTRACT

Background: Randomized trials have shown that the major antihypertensive drug classes are similarly effective to reduce mortality, but whether these drug class differences exist in clinical practice has been scarcely explored. This study evaluated the association between antihypertensive drug class, all-cause mortality and deaths due to diabetes or renal disease in real-life clinical settings.

Methods: A clinical database in Hong Kong included all patients who were prescribed their first-ever antihypertensive agents between 2001 and 2005 from the public healthcare sector. All patients were followed up for five years, and grouped according to the initial antihypertensive prescription. The associations between antihypertensive drug class, all-cause mortality or combined diabetes and renal mortality, respectively, were evaluated by Cox proportional hazard models.

Results: From 218,047 eligible patients, 33,288 (15.3%) died within five years after their first antihypertensive prescription and among which 1055 patients (0.48%) died of diabetes or renal disease. After adjusted for age, gender, socioeconomic status, service settings, district of residence, medication adherence, and the number of comorbidities, each drug class was similarly likely to be associated with mortality due to diabetes or renal disease (Adjusted Hazard Ratios (AHR) ranged from 0.92 to 1.73, p = 0.287-0.939) and all-cause mortality (AHR ranged from 0.83 to 1.02) except for beta-blockers (AHR = 0.815, 95% CI: 0.68-0.87, p = 0.024) when ACEI was used as a reference group in propensity score-adjusted analysis.

Conclusions: These findings provide real-life evidence reinforcing that any major antihypertensive drug class is suitable as a first-line agent for management of hypertension as recommended by international guidelines.

1. Introduction

Various international guidelines have recommended the choice of first-line antihypertensive agents for the management of arterial hypertension based on high quality randomized controlled trials (RCTs). The Joint National Committee (JNC) seventh report [1] and the 2009 reappraisal of the hypertension European guidelines [2] proposed thiazide diuretics, β-blockers, calcium channel blockers (CCBs), Angiotensin converting enzyme inhibitors (ACEIs) and Angiotensin receptor blockers (ARBs) as preferred first-line options. This is based on the observation in landmark RCTs that all major classes of antihypertensive drugs, except β-blockers, have been shown to reduce morbidity and mortality — and there exists few differences among them [3,4]. However, the guideline issued by the National Institute for Health and Clinical Excellence (NICE), with the assistance of the British Hypertension Society, dropped β-blockers as the first-line agent owing to its suboptimal outcomes in recent clinical trials [5].

Kaplan and Victor [6] stated that the choice of antihypertensive therapy, particularly for the first-line agent, should be made with care as more patients with less severe hypertension are being treated with medications. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) has long recognized the limitations of event-based randomized therapeutic trials [7]. These include the need to select elderly or higher risk patients to maximize the number of events collected and achieve adequate study power. As a result, younger, uncomplicated patients with lower cardiovascular risks are under-represented, and little
information is available on treatment benefits in a large number of hypertensive populations. Another important caveat is that therapeutic programs in RCTs usually diverge from usual clinical practice since drugs randomly allocated at trial commencement are continued irrespective of blood pressure lowering effects; but in clinical practice physicians normally do not continue the prescriptions which are ineffective. In trials the benefits conferred to patients are therefore diluted by the lack of benefits in non-responsive patients, and they are usually of short duration — which will imply that their generalizability to the general population is limited. These randomized trials should be interpreted in parallel with observational studies to achieve a balanced decision regarding the choice of the most preferred first-line antihypertensive agent.

The JNC eighth report is currently being prepared and the committee will decide whether β-blocker should remain as the first-line agent or relegated as a fourth-line agent. This task requires incorporation of observational studies in addition to the newer randomized outcome trials. Nevertheless, there is a scarcity of large scale observational studies which could inform guideline recommendations. We have previously studied the compliance profiles and 5 year incidence of cardiovascular mortality in a large Chinese population newly prescribed antihypertensive medications [8,9], in an attempt to provide real-life clinical data. It is presently unknown whether any major antihypertensive drug class is superior in terms of preventing deaths due to all causes, diabetes or renal diseases in non-interventional settings. The objective of this study is to test the a priori hypothesis that the incidences of all-cause mortality or deaths due to diabetes or kidney diseases, respectively, are similar among the major antihypertensive drug classes as first-line agents. The secondary objective of this study is to identify patients at higher risks for all-cause, diabetes- and renal disease-related mortality five years after antihypertensive prescriptions.

2. Methods

2.1. Data source

The computerized databases, known as electronic Clinical Management System in Hong Kong, have been previously described in details [8–15]. Briefly, these databases capture patients’ demographic parameters, prescription details, and clinical diagnoses in the forms of the International Classification of Diseases (ICD-9 and ICD-10) or the International Classification of Primary Care (ICPC-2). It serves as the sole portal of data entry which allows the linkage of physician-entered information at each patient visit in all public clinical settings among different districts. All drug prescriptions are inputted by the attending physicians and are cross-checked by dispensers or pharmacists using standardized procedures, and any amendments to the prescriptions after the initial consultations are also recorded in the system. This database was previously validated and it demonstrated a high level of completeness on the socio-demographic information (100%) and prescription profiles (99.8%) [10]. The sampling frame for the present study included the entire Hong Kong population, which is more than 7,000,000 as of 2012. Hong Kong is divided into three distinct regions, namely Hong Kong Island (most urbanized); Kowloon; and the New Territories (most rural). The ethics clearance of the study included the entire Hong Kong population, which is more than 7,000,000 as of 2012. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki.

2.2. Patients

From the database, all patients who had a consultation at any public practice and who were prescribed their first-ever antihypertensive agents between the calendar years 2001 to 2003 and in 2005 (the index date) were included. The details from the calendar year 2004 were excluded due to the substantial disruption on the clinical services as a result of the outbreak of the Severe Acute Respiratory Syndrome. Patients who received any antihypertensive medications before the index date were excluded. We captured patients who died from diabetes and renal diseases, and treated the deaths due to conditions other than these two diseases within the observation period as being censored. Each patient was allocated based on the initial prescription of antihypertensive agents, namely, α-blockers, β-blockers, thiazide diuretics, CCBs and AERIs. Patients who were prescribed ARBs and combination therapy were excluded in our data analysis because these prescriptions were relatively rare. Concomitant comorbidities include cardiovascular risk factors and medical conditions which could potentially confound the choice of antihypertensive drug class, as indicated by the respective ICPC-2 or ICD-9/ICD-10 codes. Patients were followed up until the occurrence of mortality within the study period or at the end of five years.

2.3. Outcome variables and covariates

The outcome variables were (1) all-cause mortality and (2) deaths due to diabetes mellitus (ICD-E10-E14.5) and renal diseases (ICD-9 N17–N19), respectively. The vast majority of all deaths in Hong Kong occurred in hospitals, which allows accurate case ascertainment [16]. A number of previous studies have utilized deaths in hospital as a valid proxy of patient mortality, especially for Chinese populations in which death usually occurs in hospitals [16–18]. The cause of death due to diabetes (e.g. diabetic ketoacidosis or hyperosmolar non-ketotic diabetic coma) or renal disease (e.g. uremia) was defined according to the primary cause of mortality for each patient, as determined by the physicians-in-charge when death was registered in the death certificates. The predictor variable in this study was the major class of antihypertensive drugs on its initial prescription. The interval-based proportion of days covered (PDC) was included as a covariate to take into consideration the influence of medication adherence as a potential confounder.

The PDC refers to the number of days when medication is supplied in a specified period divided by the total number of days within the period. The interval-based measure of PDC is an internationally accepted metric for assessing drug adherence in large database analysis [19–21]. In this study, a five-year interval was used for the estimation of PDC. For patients who died during the five-year period, the time period between the index date and mortality was used to estimate the PDC. Similar to the approach adopted by Mazzaglia and colleagues [22], drug adherence in the present study was divided into two levels, namely: high and intermediate (PDC ≥ 40%) or low (PDC < 40%) [23,24]. In addition, we also evaluated the rates of medication discontinuation and switching among patients. Drug switching is defined as the absence of a refill prescription in all subsequent clinic visits combined with the prescription of another antihypertensive drug of a different class since the date of the first prescription, whereas drug discontinuation refers to repeat prescription of the same drug class lasting for <80% of the days in the specified period after the first-ever antihypertensive prescription date. According to international literature, we used 1 year, 2 years, 3 years, 4 years and 5 years, respectively, as the time points for measuring these two outcomes [25–27]. The independent variables that were controlled for included patients’ age, gender, payment status (recipients vs non-recipients of comprehensive social security assistance; each consultation in a primary care setting costs approximately US$5.77, including both investigation and prescription fees), clinic type (in- and day-patient clinics, specialist outpatient clinics [SOPC], Accident and Emergency Departments [AEDs], general outpatient clinic [GOPC], and other clinic types), district of residence (Hong Kong Island vs Kowloon vs the New Territories; from the most urbanized to the most rural, respectively), the number of concomitant comorbidities, and the readings of systolic and diastolic blood pressure averaged over all clinic visits. The same list of comorbidities by their ICD-9 and ICPC-2 coding was used in the present study as published elsewhere [9], which were categorized under “Diabetes or impaired glucose tolerance” (23.00), “Cardiovascular diseases” (24.14), “Respiratory diseases” (14.65) and “Renal diseases” (11.00).

2.4. Statistical analysis

For descriptive analysis, Student’s t tests and chi-square tests of heterogeneity were used among two or more continuous and categorical variables, respectively. All the variables listed above were entered into one Cox-proportional hazard model to explore the association between initial antihypertensive drug class and mortality. All cause mortality and combined deaths due to diabetes and renal disease, respectively, were the outcome variables. To account for the confounding effects of medication change, all study participants were censored if they switched study medications, discontinued treatment (in which case they were followed for 100 days from their last prescription to identify events that may have precipitated discontinuation), commenced treatment with a different antihypertensive agent, or reached the end of the study. This is according to a methodology adopted by Dhalla et al. [25], and we followed patients for a maximum of 5 years. Also, we have conducted a sensitivity analysis where patients whose antihypertensive drug class has been switched or added on by another drug class were excluded, and a similar regression model was constructed to detect if there were any changes in the associated factors identified.

In addition, a propensity score model was developed to estimate weightings for adherence selection, namely high and intermediate vs low adherence, given the possible existence of treatment indication bias due to the observational nature of the study. Therefore, the analysis was performed with adjusted estimates weighted by the inverse estimated propensity scores in two Cox proportion hazard models according to standard statistical methodology [26,27]. To further minimize the influence of indication bias due to the confounding factors of baseline characteristics of patients, a high-dimensional propensity score matching to compare patients with similar observed characteristics was adopted using standardized methodology as utilized in other literature [25,28,29]. Each recipient of one antihypertensive drug class was matched with a recipient on another antihypertensive class on the basis of age at index date (within 1 year), sex, calendar year of treatment initiation, and propensity score (within 0.2 SD).

We evaluated for multicollinearity and interactions among variables to ensure the robustness of the regression model. The Statistical Package for Social Sciences version 16.0 (SPSS, Inc.) was used for all data analyses. All p values < 0.05 were regarded as statistically significant.
3. Results

3.1. Participant characteristics and medication changes

A total of 218,047 eligible patients were included (Table 1). There were only female patients (54.9%) and 52.6% were aged 60 years or older. Only 15.2% received public assistance and the majority was followed up at in- or day-patient clinics and specialized out-patient clinics (59.9%). Most patients lived in the more rural regions (48.6% and 33.9% in the New Territories and Kowloon, respectively). The most commonly prescribed antihypertensive agent was beta-blockers (45.2%), CCBs (30.1%), followed by ACEIs (10.5%) and thiazide diuretics (8.0%). 6.2% of all patients were prescribed alpha-blocker as a first-line agent. Most patients (67.1%) had intermediate to good adherence, and the majority had one comorbidity or less (92.6%). Table 2 shows the cumulative incidence of medication discontinuation and switching. In both short- and long-term, users of alpha-blockers and beta-blockers had the highest discontinuation rates, whereas thiazide diuretics and ACEIs had the highest switching rates.

3.2. Profiles of all-cause mortality and deaths due to diabetes and renal diseases

A total of 33,288 patients (15.3%) died within five years after their first-ever antihypertensive prescription (Table 3); and among which 1055 died due to diabetes or renal diseases. From univariate analysis, elderly patients (p < 0.001), male subjects (p = 0.001 to 0.033) and those receiving social security allowance (p < 0.001) were more likely to experience all-cause mortality or deaths due to diabetes or renal diseases. In addition, patients attending in-patient or day-patient clinics and specialized out-patient clinics were more likely to suffer from mortality (p < 0.001). The district of residence and the adherence levels to antihypertensive agents were also significant factors. The proportions of patients who died increased with the number of comorbidities in a steep dose–response manner. The proportions of all-cause mortality were the highest among users of CCBs (22.9%), ACEIs (22.4%), and alpha-blockers (19.2%), followed by thiazide diuretics (14.3%) and beta-blockers (8.2%). Regarding deaths due to diabetes or renal diseases (Table 3), patients prescribed CCBs (0.9%) and ACEIs (0.7%) had the highest rates of mortality, followed by thiazide diuretics (0.6%), alpha-blockers (0.4%) and beta-blockers (0.2%) (both p < 0.001).

3.3. Factors associated with all-cause mortality or deaths due to diabetes or renal diseases

From Cox Proportional Hazard analysis with all-cause mortality as the outcome measure (Table 4), it was found that advanced age (50–59 years; adjusted hazard ratio [AHR] = 1.924, 95% CI: 1.639–2.259; 60–69 years; AHR = 3.401, 95% CI: 2.803–4.126; ≥70 years; AHR = 8.844, 95% CI: 7.348–10.645, all p < 0.001; referent < 50 years), male gender (AHR for female = 0.657, 95% CI: 0.632–0.682, p < 0.001), recipients of public assistance (AHR = 1.375, 95% CI: 1.320–1.433, p < 0.001), attendance in in-patient or day-patient service (AHR = 2.316, 95% CI: 2.141–2.506, p < 0.001) and the presence of at least one comorbidity (AHR ranged from 1.266 to 1.314, p < 0.001) were significantly associated with all-cause deaths. Patients attending general outpatient clinics (AHR = 0.815, 95% CI: 0.683–0.874, p = 0.024). However, when the group of beta-blockers was confined to the centrally-acting agents, its relative hazard became insignificant (AHR = 1.141, 95% CI: 0.940–1.384, p = 0.182). For deaths due to diabetes or renal diseases, the associated factors were similar except gender, receipt of public assistance and medication adherence which did not report statistical significance. When compared with ACEIs, the various drug classes were similarly associated with combined diabetes and renal mortality (AHR ranged from 1.226 to 2.233, p = 0.143 to 0.842).

When high-dimensional propensity score matching is used to compare patients with similar characteristics, the factors associated with both outcomes and the drug class comparison remain unchanged. In addition, sensitivity analysis by exclusion of patients whose medication was switched or added on by another drug class detected no difference in the associated factors identified. There exists no interaction or multicollinearity among the predictor variables, implying the regression analysis is robust.

4. Discussion

4.1. Major findings

The present findings showed that in general, the major classes of antihypertensive agents were similarly likely to be associated with all-cause mortality and deaths due to diabetes and renal diseases when used as first-line agents among antihypertensive-naïve patients. Patients receiving beta-blockers seem to suffer from lower incidence of all-cause mortality but this is not the case with centrally-acting agents. In addition, some factors associated with mortality was identified, including old age, presence of comorbidities and the healthcare setting being in secondary care. These results, based on observations from non-interventional settings, bear significant implications for clinicians on the choice of first-line antihypertensive prescriptions.
4.2. Relationship to existing literature—all-cause mortality, renal disease and diabetes mellitus

A recent meta-analysis of RCTs comparing the incidence of all-cause mortality among the major antihypertensive drug classes [3] showed that there was no difference between patients initially prescribed beta-blockers, diuretics and renin-angiotensin system inhibitors, and the all-cause mortality rate was only marginally higher for beta-blockers compared to CCB (relative risk 1.07, 95% CI 1.00 to 1.14; I(2) = 2%). However, the authors recognized that the GRADE evidence of these findings were low and achieved mid-level evidence only, indicating that the true effect of beta-blockers may be substantially different from the review estimates [30]. Another meta-analysis involving 127 studies corresponding to 150 group comparisons with a weighted mean follow-up of 4.2 years [31] demonstrated that there exists a slightly smaller risk of end-stage renal failure among ACEI or ARB users than other antihypertensive users (relative risk 0.87, 95% CI. 0.75–0.99, p = 0.40). The ACEI or ARB group was also associated with a statistically significant smaller serum creatinine change (−7.07 μmol/L, 95% CI. −13.26 to −0.88) and also urine albumin excretion (−15.37 mg/day, 95% CI. −24.72 to −6.74). However, these benefits have been attributed to lowering of blood pressure per se rather than the antihypertensive drug class used. In a post-hoc analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) among hypertensive patients aged 55 years or older with at least one cardiovascular risk factor, there were no significant differences found in the incidence of end-stage renal failure or decrement in glomerular filtration rates [32]. Furthermore, there is one significant factor which could potentially favor the effectiveness of β-blockers on reducing mortality, namely the national salt intake level. Dietary salt intake in Hong Kong was high at the time the study participants were recruited. The average sodium intake of the Hong Kong population is 203 mmol/day (4.67 g/day) [33], which is higher than western countries and also the level recommended by the WHO (<2 g/day) [34]. The findings should therefore be interpreted in the light of this potential confounder.

Turning to the incidence of diabetes—from the ALLHAT trial, patients without diabetes at baseline have higher incidence of diabetes at 4 years in the thiazide diuretic group (11.0%) than the CCB (9.3%) and ACEI group (7.8%) [35]. Nevertheless, these and other metabolic differences did not translate into any overall disadvantages for the thiazide diuretic group after the average follow-up of 4.9 years. Furthermore, additional epidemiological analysis examining the association of 2 year fasting glucose changes with cardiovascular disease and renal events reported no significance overall and separately in the diuretic group [36]. Also, among those who developed incident diabetes by 2 years compared with those who did not, there was no subsequent increase in risks for any major disease outcomes and mortality, with an exception of congestive heart failure [37]. Thus far, we are not aware of any large-scale observational studies comparing these major antihypertensive drug classes on mortality rates.

---

Table 2

| Year | Discontinuation | Switching |
|------|-----------------|-----------|
|      | ACEI (22,985)   | CCB (65,535) |
|      | β-Blockers (19,894) | Thiazide (17,445) |
|      | α-Blockers (13,455) |  |
| 1    | 7175 (32.1%)    | 32,364 (49.4%) |
| 2    | 8639 (37.6%)    | 35,061 (53.6%) |
| 3    | 9366 (40.8%)    | 36,712 (56.1%) |
| 4    | 9739 (42.4%)    | 37,493 (57.3%) |
| 5    | 10,023 (43.6%)  | 38,048 (58.1%) |

ACEI: Angiotensin Converting Enzyme Inhibitors; CCB: Calcium channel blockers.

Table 3

| Co-morbidity | All-caused mortality (n = 33,288) | Mortality due to diabetes or renal disease (n = 1055) |
|--------------|-----------------------------------|---------------------------------------------------|
|               | N (%)                             | p                                  |
| Gender       |                                   |                                    |
| Male         | 18,864 (19.2%)                    | 510 (0.52%)                        | 0.033 |
| Female       | 14,424 (12.0%)                    | 545 (0.46%)                        |          |
| Age (years)  |                                   |                                    |
| <50          | 1663 (2.7%)                       | 29 (0.00%)                         | <0.001 |
| 50–59        | 2265 (5.4%)                       | 41 (0.11%)                         |          |
| 60–69        | 4646 (11.2%)                      | 126 (0.3%)                         |          |
| ≥70          | 24,713 (33.9%)                    | 859 (1.2%)                         |          |
| Public assistance |                               |                                    |
| Yes          | 10,110 (30.8%)                    | 322 (1.0%)                         | <0.001 |
| No           | 22,640 (12.4%)                    | 720 (0.4%)                         |          |
| Service type on first visit |                     |                                    |
| In-/day-patient clinic | 22,776 (34.7%) | 707 (1.1%)                      | <0.001 |
| Special out-patient clinic | 5056 (7.6%)   | 216 (0.3%)                      |          |
| Accident and Emergency | 945 (5.6%)   | 25 (0.13%)                      |          |
| Department   | 3669 (5.7%)                       | 80 (0.13%)                         |          |
| General outpatient clinics | 3839 (12.0%) | 27 (0.05%)                      |          |
| Others       | 839 (12.0%)                       | 27 (0.05%)                         |          |
| District of residence |                                  |                                    |
| Hong Kong    | 6112 (12.0%)                      | 191 (0.53%)                        | <0.001 |
| Kowloon      | 12,967 (17.6%)                    | 407 (0.60%)                        |          |
| New Territories | 14,209 (13.4%) | 457 (0.40%)                      |          |
| First prescription |                               |                                    |
| ACEIs        | 5144 (22.4%)                      | 157 (0.77%)                        | <0.001 |
| Alpha blocker| 2579 (19.2%)                      | 59 (0.46%)                         |          |
| Beta blocker | 8091 (8.2%)                       | 173 (0.25%)                        |          |
| CCB          | 14,974 (22.9%)                    | 566 (0.94%)                        |          |
| Thiazide     | 2500 (14.0%)                      | 100 (0.60%)                        |          |
| Proportion of days covered |                                 |                                    |
| <40%         | 10,290 (14.4%)                    | 285 (0.40%)                        | <0.001 |
| ≥40%         | 22,998 (15.7%)                    | 770 (0.55%)                        |          |
| ACEI: Angiotensin converting enzyme inhibitors; CCB: Calcium channel blocker.
4.3. Study limitations

This is the first and the largest observational study evaluating the factors associated with all-cause and non-cardiovascular mortality in a large Chinese population. The completeness of the database and the good dispensing practice make the study findings more robust. In addition, the accuracy of the independent variable (antihypertensive drug class) and the outcome measures (mortality) further strengthen the results. However, some of the limitations should be addressed. Firstly, we assume that patients were taking the medications prescribed as they were documented in the database which is an inherent assumption for database studies. Furthermore, the dataset does not consist of all potential confounders which could be controlled, such as the severity of comorbidity, the blood pressure levels, and some covariates including lifestyle factors which were not routinely captured in clinical databases. Moreover, indication bias for treatment according to medication classes exists despite the use of propensity scores. One might also argue that the duration of observing mortality for only 5 years after initial antihypertensive prescriptions might not be long enough to capture clinically meaningful outcomes, and prolonging the observational period is warranted in future studies.

5. Conclusions: implications to clinical practice

The present findings showed that all major drug classes were similar in terms of all-cause as well as combined diabetes and renal mortality, respectively. These observational data further strengthened the findings from RCTs which were conducted in interventional settings. Our findings are therefore compatible with the international guidelines. Physicians should not be deterred to prescribe beta-blockers as the first-line antihypertensive drug for management of arterial hypertension. The study added evidence to the existing findings from event-based randomized therapeutic trials, that any major antihypertensive drug class is suitable as a first-line agent for managing hypertension.

Acknowledgments

We would like to thank the Health Informatics Section of the Hospital Authority Information Technology Services for their permission to utilize the computer dataset. We also expressed our gratitude to all physicians who have participated in the data entry.

References

[1] Chobanian AV, Bakris GL, Black HR, et al. Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on prevention, detection, evaluation, and the treatment of high blood pressure. Hypertension 2003;42:1206–52.

[2] Mancia G, Laurent S, Agabiti-Rosei E Ambrosioni E, et al. European Society of Hypertension. Reappraisal of European guidelines on hypertension management: European Society of Hypertension Task Force document. J Hypertens 2009;27:2121–58.

[3] Blood Pressure Trialist. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008;336:1121–3.

[4] Task Force. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105–87.

[5] National Collaborating Centre for Chronic Conditions. Hypertension: clinical management of primary hypertension in adults. NICE guideline draft. Available at
Mazzaglia G, Ambrosioni E, Alacqua M, et al. Adherence to antihypertensive medication: a five-year cohort study. Int J Cardiol 2012. http://dx.doi.org/10.1016/j.ijcard.2012.10.048.

Schooling CM, Lam TH, Li ZB, et al. Obesity, physical activity, and mortality in a prospective Chinese elderly cohort. Arch Intern Med 2006;166:1498–504.

Choudhry NK, Shrank WH, Levin RL, et al. Measuring concurrent adherence to multiple related medications. Ann Manag Care Pharm 2009;15(20):457–64.

Martin BC, Wiley-Exley EK, Richards S, Domino ME, Carey TS, Sleath BL. Contrasting measures of adherence with sampling drug use, medication switching and therapeutically. Ann Pharmacother 2009;43:36–44.

Mazzaglia G, Ambrosioni E, Alacqua M, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation 2009;120:1598–605.

Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 2007;297:177–86.

Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoeconom Drug Saf 2006;15:355–76.

Burke TA, Sturkenboom MC, Lu S, Wentworth CE, Lin Y, Rhoads GG. Discontinuation of antihypertensive drugs among newly diagnosed hypertensive patients in UK general practice. J Hypertens 2006;24:1193–200.

Mazzaglia G, Mantovani LG, Sturkenboom MC, et al. Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. J Hypertens 2005;23:2093–100.

Wong MC, Tam WW, Cheung CS, et al. Initial antihypertensive prescription and switching: a 5 year cohort study from 250,851 patients. PLoS One 2013;8:e53625.

Dhalla IA, Gomes T, Yao Z, et al. Chlorothalidone versus hydrochlorothiazide for the treatment of hypertension in older adults. Ann Intern Med 2013;158:447–55.

Curtis LH, Hammill BG, Eisenstein EL, Kramer JM, Anstrom KJ. Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases. Med Care 2007;45:S103–7.

D’Agostino RB. Propensity scores in cardiovascular research. Circulation 2007;115:2340–3.

Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 2009;20:512–22.

Gomes T, Juarink DN, Ho JM, Schneeweiss S, Mandani MM. Risk of serious falls associated with oxybutynin and tolterodine: a population based study. J Urol 2011;186:1340–4.

Wyssonge CS, Bradley HA, Volmink J, Mayosi BM, Mbewu A, Opie LH. Beta-blockers for hypertension. Cochrane Database Syst Rev 2012;8:CD002003.

Casas JP, Chua W, Lourdesgeorgis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005;366:2026–33.

Rahman M, Presiel S, Davis BR, et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005;165:936–46.

Cheung BM, McGhee SM, Las CP, Ng P. Cost-effectiveness of low-salt diet for lowering blood pressure in the Hong Kong Chinese population. Hong Kong Med J 2007;13:532–6.

Elliott P, Brown I. Sodium intakes around the world. Background document prepared for the forum and technical meeting on reducing salt intake in populations (Paris 5–7th October 2006). World Health Organization; 2006. [Available at: http://www.who.int/dietphysicalactivity/Elliott-brown-2007.pdf. Accessed on 08 May 2013].

Cutler JA, Davis BR. Thiazide-type diuretics and β-adrenergic blockers as first-line drug treatments for hypertension. Circulation 2008;117:2891–705.